SIRION Biotech
22 articles with SIRION Biotech
-
PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy
2/16/2022
PerkinElmer, Inc. today announced that its SIRION Biotech business have entered into an agreement to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas.
-
It's been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.
-
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
6/22/2021
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
-
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
SIRION Biotech GmbH Licensed Its LentiBOOST™ Transduction Technology to Cellectis
1/7/2021
Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. SIRION is entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sa
-
BioSpace Global Roundup, Oct. 8
10/8/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
BioSpace Global Roundup, July 16
7/16/2020
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines. -
Munich and Boston-Based Viral Vector Pioneer Achieves 26% Growth for H1 2020 Despite COVID-19 Pandemic
7/14/2020
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene and cell therapy, announced financial results for the first half of 2020.
-
BioSpace Global Roundup, April 9
4/9/2020
Biopharma companies from across the globe provide updates to their business operations and pipelines. -
Beam Therapeutics Licenses SIRION Biotech’s LentiBOOST™ Technology for its CAR-T pipeline
4/7/2020
SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products. CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing technology. Under the terms of this agreement, SIR
-
SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)
2/4/2020
SIRION Biotech GmbH and InProTher Aps announced a broad licensing agreement which includes coverage of SIRION’s adenovirus technologies to cancer vaccines encoding Endogenous Retrovirus -derived antigens for active immunotherapy.
-
SIRION Biotech Continues to Expand into the U.S. Viral Vector Market
10/31/2019
Dr. Carl Christel Heads U.S. Office and Hires Rajesh Panigrahi and Roman Braun
-
SIRION Biotech to Participate in Major International Industry Conferences
10/1/2019
SIRION Biotech GmbH announced its participation in major international conferences this October.
-
Gene and Cell Therapy Solutions Provider, SIRION Biotech Announces Record First Half 2019 Financial Results
7/31/2019
Viral Vector Engineer Gains Momentum from its Technology, LentiBoost™ with 100% Growth
-
1Q2019 Life Science Growth Announcements
4/18/2019
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry. -
Sirion Biotech International threw a Bavarian-themed grand opening party at the Forsythe Institute on Feb. 1. The new headquarters are in Cambridge, Mass and currently have five employees.
-
SIRION Biotech Expands US Presence in Massachusetts
2/1/2019
Europe’s Leading Commercial Provider of Viral Vector Technology Opens Local Office in Cambridge
-
SIRION Biotech Names LaVoieHealthScience as Strategic Communications Agency of Record
12/5/2018
SIRION Biotech Plans Path for U.S. Market Expansion
-
BIO2015: SIRION Biotech Sets Up Shop in Boston Bio-Hub and Plans for 25 New Hires
6/18/2015